Age: 0.25
Sex: F
Vaccine: HEP
Symptoms: Hepatitis B surface antibody negative, Inappropriate schedule of product administration, Incorrect dose administered
Clinical narrative: the patient was nonimmune; he first dose {1ml) was administered on 9/23/2022, second dose {1ml) was administered on 1/10/2023,; The caller said the patient inadvertently received a 0.5ml dose of RECOMBIVAX HB for the administered on 5/15/2023; The first dose {1ml) was administered on 9/23/2022, second dose {1ml) was administered on 1/10/2023; first dose of RECOMBIVAX HB on 4/5/2002, second dose on 6/4/2002, and third dose on 12/10/2002; first dose of RECOMBIVAX HB on 4/5/2002, second dose on 6/4/2002; This spontaneous report was received from a nurse referring to a currently 21-year-old female patient. The patient's medical history, historical drugs, past drug reactions or allergies, concurrent conditions, and concomitant drugs were not reported.   On 05-APR-2002, the patient was vaccinated with her first dose of Hepatitis B Vaccine (Recombinant) (HBVAXPRO HB) intramuscular injection (strength, dose, route of administration, anatomical location, lot#, and expiration date were not reported) for hepatitis b vaccination. On 04-JUN-2002, the patient was vaccinated with her second dose of Hepatitis B Vaccine (Recombinant) (HBVAXPRO HB) intramuscular injection (strength, dose, route of administration, anatomical location, lot#, and expiration date were not reported) for hepatitis b vaccination (inappropriate schedule of product administration). On 10-DEC-2002, the patient was vaccinated with her third dose of Hepatitis B Vaccine (Recombinant) (HBVAXPRO HB) intramuscular injection (strength, dose, route of administration, anatomical location, lot#, and expiration date were not reported) for hepatitis b vaccination (inappropriate schedule of product administration).  On an unknown date, the patient had a titer done that showed that the patient was nonimmune (hepatitis B surface antibody negative) thus the patient was vaccinated with 3 additional doses of Hepatitis B Vaccine (Recombinant) (HBVAXPRO HB). On 23-SEP-2022, the patient was vaccinated with her first dose of Hepatitis B Vaccine (Recombinant) (HBVAXPRO HB) intramuscular injection (1 ml; strength, route of administration, anatomical location, lot#, and expiration date were not reported) for hepatitis b vaccination. On 10-JAN-2023, the patient was vaccinated with her second dose of Hepatitis B Vaccine (Recombinant) (HBVAXPRO HB) intramuscular injection (1 ml; strength, route of administration, anatomical location, lot#, and expiration date were not reported) for hepatitis b vaccination (inappropriate schedule of product administration). On 15-MAY-2023, the patient was vaccinated with her third dose of Hepatitis B Vaccine (Recombinant) (HBVAXPRO HB) intramuscular injection inadvertently (0.5 ml; strength, route of administration, anatomical location, lot#, and expiration date were not reported) for hepatitis b vaccination (inappropriate schedule of product administration and incorrect dose administered). The outcome of hepatitis B surface antibody negative, and the causal relationship between the event and Hepatitis B Vaccine (Recombinant) (HBVAXPRO) was not reported.